NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain; BTI Biotechnology Institute, Vitoria, Spain; Joint first authors and contributed equally to the paper.
NsGene,225 Chapman Street, Providence, RI, USA; Joint first authors and contributed equally to the paper.
Trends Biotechnol. 2018 Apr;36(4):445-456. doi: 10.1016/j.tibtech.2018.01.007. Epub 2018 Feb 15.
Encapsulating, or immunoisolating, insulin-secreting cells within implantable, semipermeable membranes is an emerging treatment for type 1 diabetes. This approach can eliminate the need for immunosuppressive drug treatments to prevent transplant rejection and overcome the shortage of donor tissues by utilizing cells derived from allogeneic or xenogeneic sources. Encapsulation device designs are being optimized alongside the development of clinically viable, replenishable, insulin-producing stem cells, for the first time creating the possibility of widespread therapeutic use of this technology. Here, we highlight the status of the most advanced and widely explored implementations of cell encapsulation with an eye toward translating the potential of this technological approach to medical reality.
将分泌胰岛素的细胞封装在可植入的半透性膜内，即免疫隔离，是治疗 1 型糖尿病的一种新兴方法。这种方法可以消除对免疫抑制药物治疗的需求，以防止移植排斥，并通过利用来自同种异体或异种来源的细胞来克服供体组织的短缺。封装设备的设计正在与临床可行、可再生、产生胰岛素的干细胞的开发一起进行优化，首次为该技术的广泛治疗应用创造了可能。在这里，我们重点介绍细胞封装的最先进和广泛探索的实施情况，以期将这种技术方法的潜力转化为医学现实。
